IP Library › Patent Application 19304835
Patent Application
App. No. 19/304,835

MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
19/304,835
Abstract

The present invention provides compounds, compositions thereof, and methods of using the same.

Claims (21)

1 . A method of eliciting a rapid-onset antidepressant activity in a patient in need thereof suffering from treatment-resistant depression, said method comprising administering to said patient a compound of formula I-90 or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable composition thereof:

2 - 19 . (canceled)

20 . The method of claim 1 , wherein said method further comprises administering to said patient an additional therapeutic agent or therapy.

21 . The method of claim 1 , wherein said rapid-onset antidepressant activity occurs within two weeks of administration of said compound of formula I-90 or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable composition thereof.

22 . The method of claim 1 , wherein said rapid-onset antidepressant activity occurs within one week of administration of said compound of formula I-90 or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable composition thereof.

23 . The method of claim 1 , wherein said rapid-onset antidepressant activity occurs within seven days of administration of said compound of formula I-90 or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable composition thereof.

24 . The method of claim 1 , wherein said rapid-onset antidepressant activity occurs within six days of administration of said compound of formula I-90 or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable composition thereof.

25 . The method of claim 1 , wherein the rapid-onset antidepressant activity occurs within seven days of administration of said compound of formula I-90 or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable composition thereof.

26 . The method of claim 1 , wherein said rapid-onset antidepressant activity occurs within five days of administration of said compound of formula I-90 or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable composition thereof.

27 . The method of claim 1 , wherein said rapid-onset antidepressant activity occurs within four days of administration of said compound of formula I-90 or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable composition thereof.

28 . The method of claim 1 , wherein said rapid-onset antidepressant activity occurs within three days of administration of said compound of formula I-90 or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable composition thereof.

29 . The method of claim 1 , wherein said rapid-onset antidepressant activity occurs within two days of administration of said compound of formula I-90 or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable composition thereof.

30 . The method of claim 1 , wherein said rapid-onset antidepressant activity occurs within one day of administration of said compound of formula I-90 or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable composition thereof.

31 . The method of claim 1 , wherein said rapid-onset antidepressant activity occurs within less than twenty-four hours of administration of said compound of formula I-90 or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable composition thereof.

32 . The method of claim 1 , wherein said rapid-onset antidepressant activity is both rapid-onset antidepressant activity and long-lasting, sustained antidepressant activity.

33 . The method of claim 32 , wherein said long-lasting, sustained antidepressant activity persists for at least twenty-four hours after administration of said compound of formula I-90 or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable composition thereof.

34 . The method of claim 32 , wherein said long-lasting, sustained antidepressant activity persists for longer than one day after administration of said compound of formula I-90 or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable composition thereof.

35 . The method of claim 32 , wherein said long-lasting, sustained antidepressant activity persists for at least two days after administration of said compound of formula I-90 or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable composition thereof.

36 . The method of claim 32 , wherein said long-lasting, sustained antidepressant activity persists for at least three days after administration of said compound of formula I-90 or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable composition thereof.

37 . The method of claim 32 , wherein said long-lasting, sustained antidepressant activity persists for at least four days after administration of said compound of formula I-90 or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable composition thereof.

38 . The method of claim 32 , wherein said long-lasting, sustained antidepressant activity persists for at least five days after administration of said compound of formula I-90 or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable composition thereof.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 6, 2026
From: NAVITOR PHARMACEUTICALS, INC.
To: SUPERNUS PHARMACEUTICALS, INC.
Reel/Frame 075552/0122 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 27, 2025
From: SAIAH, EDDINE; VLASUK, GEORGE
To: NAVITOR PHARMACEUTICALS, INC.
Reel/Frame 072598/0053 →